Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$147.68
+0.9%		$139.26
$108.46
▼
$157.29
$181.41B0.335.09 million shs5.19 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.88
+0.8%		$137.55
$77.58
▼
$156.92
$354.75B0.2110.59 million shs7.22 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.94%+1.39%+6.31%+19.33%+33.21%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.67%-1.91%+6.46%+27.04%+78.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$147.68
+0.9%		$139.26
$108.46
▼
$157.29
$181.41B0.335.09 million shs5.19 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.88
+0.8%		$137.55
$77.58
▼
$156.92
$354.75B0.2110.59 million shs7.22 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.94%+1.39%+6.31%+19.33%+33.21%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.67%-1.91%+6.46%+27.04%+78.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.86
Moderate Buy$158.787.51% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.71
Moderate Buy$154.246.46% Upside

Current Analyst Ratings Breakdown

Latest MRK and GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
9/10/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$155.00 ➝ $175.00
9/10/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$150.00 ➝ $172.00
9/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$127.00 ➝ $161.00
9/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$146.00 ➝ $170.00
9/4/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$150.00 ➝ $170.00
8/31/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$155.00 ➝ $180.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $170.00
8/21/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $160.00
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B6.22$10.57 per share13.97$18.23 per share8.10
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.50$11.51 per share12.59$21.22 per share6.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A14.96N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25115.9015.006.264.77%16.73%6.13%10/29/2026 (Estimated)

Latest MRK and GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.22%+3.04%N/A 10 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.35%+5.75%272.00%14 Years

Latest MRK and GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.36%9/15/20269/15/202610/7/2026
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.24%9/15/20269/15/20269/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable

Recent News About These Companies

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%
September 16 at 6:04 PM  |  barchart.comhttps://www.barchart.com/story/news/4633663/this-dividend-stock-is-beating-the-market-in-2026-and-yields-2-36
Brokerages Set Merck & Co., Inc. (NYSE:MRK) Price Target at $151.32
September 16 at 4:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027040
Merck & Co., Inc. Sees Unusually High Options Volume (NYSE:MRK)
September 16 at 3:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31026503
RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)
September 16 at 1:11 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/4624971/rbc-capital-sticks-to-their-hold-rating-for-merck-company-mrk/
Oncology Tie-Up and Blockchain Pilot Might Change The Case For Investing In Merck (MRK)
September 16 at 1:11 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oncology-tie-blockchain-pilot-might-021221229.html
Merck Stock: Is The $70 Billion Pipeline Worth the Premium?
September 16 at 1:11 AM  |  trefis.comT
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
September 15 at 3:10 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immunocore-hits-enrollment-target-kimmtrak-152200138.html
Merck & Co Inc's Dividend Analysis
September 15 at 10:09 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/merck-co-incs-dividend-analysis-110052740.html
Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030
September 15 at 8:30 AM  |  247wallst.comhttps://247wallst.com/investing/2026/09/15/eli-lilly-vs-merck-one-is-a-no-brainer-to-hold-through-2030/?utm_source=snapi
Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14 at 6:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4946226-merck-and-co-inc-mrk-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Merck & Co., Inc. Target of Unusually Large Options Trading (NYSE:MRK)
September 14 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-merck-co-inc-target-of-unusually-large-options-trading-nyse-mrk-2026-09-14/
Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation
September 14 at 5:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-merck-ceo-sees-pipeline-upside-as-launches-animal-health-drive-transformation-2026-09-14/
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
September 14 at 4:06 PM  |  pymnts.comhttps://www.pymnts.com/healthcare/2026/modernas-ai-built-cancer-vaccine-clears-phase-3-with-merck/?utm_source=snapi
Merck & Co. stock gains as DBS lifts price target and Q2 2026 revenue grows
September 14 at 9:44 AM  |  ad-hoc-news.deA
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
September 14 at 9:44 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/perspective-therapeutics-announces-clinical-collaboration-101600551.html
Smartphone displaying a rising stock price chart on a desk with glasses, a financial newspaper, and a notebook.
Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains (MRK)
...
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/blue-chip-stocks-are-looking-anything-but-boring-with-dividends-and-big-2026-gains/
DBS Keeps Their Buy Rating on Merck & Company (MRK)
September 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/4574497/dbs-keeps-their-buy-rating-on-merck-company-mrk/
Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock
September 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/jim-cramer-explains-why-merck-164911925.html
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
September 12, 2026  |  youtube.comY
Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, HSBC Analyst Says
September 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31018372
Wall Street Zen Downgrades Merck & Co., Inc. (NYSE:MRK) to Hold
September 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31017930

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$147.68 +1.38 (+0.94%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$147.89 +0.21 (+0.14%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$144.88 +1.09 (+0.75%)
Closing price 09/16/2026 03:59 PM Eastern
Extended Trading
$145.90 +1.03 (+0.71%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas